PharmaRadar360

PharmaRadar360

🇺🇸·19h agoResearch

NCT04923893: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Thera

Study type: INTERVENTIONAL. Phase: PHASE3.

Publisher

C
ClinicalTrials.gov

USA

This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
ClinicalTrials.gov
Region
USA
Scope
Research
Published
September 25, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Study type: INTERVENTIONAL. Phase: PHASE3.

Source route

Continue on clinicaltrials.gov

Leave the platform to read the original full article on the publisher site.

Source: ClinicalTrials.gov

Scope: Research

Open original article
NCT04923893: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Thera | PharmaRadar360